Related Experiment Video
Updated: Feb 2, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study
Jungmee Kim1, Ji Hwan Bang2, Ju Young Shin3
1Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
Insights
Abacavir use in HIV patients does not increase hypertension risk overall. However, poor adherence, antibiotic use, male sex, and older age are associated with increased hypertension risk when using abacavir.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- HIV infection is linked to increased cardiovascular disease (CVD) risk.
- Abacavir's association with hypertension is not well-established.
- This study investigates hypertension risk in HIV patients using abacavir-based antiretroviral therapy (ART).
Purpose of the Study:
- To evaluate the risk of hypertension associated with abacavir use.
- To compare hypertension incidence between abacavir and non-abacavir ART regimens.
- To identify subgroups at higher risk of hypertension with abacavir.
Main Methods:
- Analysis of a nationwide cohort of 6493 HIV-infected individuals initiating ART.
- Hypertension-free participants at baseline were followed from 2008-2016.
- Cox proportional hazard models assessed hypertension risk (HRs) with time-varying ART exposure.
Main Results:
- Hypertension incidence rates were 4.6 per 100 person-years for abacavir users vs. 3.6 for non-abacavir users.
- Abacavir did not significantly increase overall hypertension risk (HR 1.2, p=0.061).
- Increased risk observed with poor ART adherence (HR 1.9), prophylactic antibiotics (HR 1.2), male sex, age ≥40, and urban tertiary hospital visits.
Conclusions:
- Abacavir is not associated with increased hypertension risk in the general HIV population.
- Specific factors like poor ART adherence, antibiotic use, male sex, and older age increase hypertension risk in abacavir-treated patients.
- These factors warrant careful monitoring for hypertension in patients on abacavir.
Purpose:
A high risk of cardiovascular disease (CVD) is reported for HIV-infected individuals. While a link between abacavir and CVD risk is suggested, an association between abacavir and hypertension remains unclear. This study evaluated hypertension risk with abacavir use in comparison to non-abacavir antiretroviral treatment (ART).
Materials And Methods:
From a nationwide cohort of HIV-infected individuals on their initial ART, 6493 who were free of hypertension at baseline were analyzed. The use of ART was treated as a time-varying covariate measured as a daily unit. Incidence rate of hypertension was calculated, and Cox proportional hazard models were used to estimate adjusted hazard ratios (HRs) with 95% confidence interval (CI) of incident hypertension overall and among subgroups.
Results:
From the 6493 participants, 24072 person-years (PY) of follow-up were contributed during 2008-2016. The incidence rates of hypertension were 4.6 and 3.6 per 100 PY for abacavir and non-abacavir ART users, respectively. The population attributable fraction of abacavir use on hypertension was 12%. Abacavir exposure did not elevate the risk of hypertension among overall study population [HR, 1.2 (95% CI, 1.0-1.4), p=0.061]. However, those with poor ART adherence, defined as a medication possession ratio <50% [HR, 1.9 (95% CI, 1.5-2.4), p<0.0001] or requiring prophylactic antibiotics [HR, 1.2 (95% CI, 1.0-1.3), p=0.023], were at risk of hypertension induced by abacavir, as were men, individuals aged ≥40 years, and patients visiting tertiary hospitals in urban areas.
Conclusion:
When present, poor ART adherence, requiring prophylactic antibiotics, male sex, and older age may warrant additional concern for hypertension in patients treated with abacavir.
More Related Videos
13:58Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Impact of Individuals on Individuals
Relative Risk
Hypertension I: Introduction
Hypertension II: Pathophysiology